Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Retained Earnings (2020 - 2025)

Insight Molecular Diagnostics' Retained Earnings history spans 6 years, with the latest figure at -$377.8 million for Q3 2025.

  • For Q3 2025, Retained Earnings fell 662907.02% year-over-year to -$377.8 million; the TTM value through Sep 2025 reached -$377.8 million, down 662907.02%, while the annual FY2024 figure was -$350.5 million, 20.93% down from the prior year.
  • Retained Earnings for Q3 2025 was -$377.8 million at Insight Molecular Diagnostics, down from -$367.0 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $57000.0 in Q3 2024 and bottomed at -$377.8 million in Q3 2025.
  • The 5-year median for Retained Earnings is -$260.7 million (2022), against an average of -$215.7 million.
  • The largest annual shift saw Retained Earnings tumbled 1379547.37% in 2023 before it surged 100.02% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$187.8 million in 2021, then crashed by 38.82% to -$260.7 million in 2022, then dropped by 11.2% to -$289.9 million in 2023, then dropped by 20.93% to -$350.5 million in 2024, then decreased by 7.78% to -$377.8 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Retained Earnings are -$377.8 million (Q3 2025), -$367.0 million (Q2 2025), and -$357.2 million (Q1 2025).